Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
Products for Apoptosis
- Caspase(99)
- 14.3.3 Proteins(1)
- Apoptosis Inducers(43)
- Bax(7)
- Bcl-2 Family(120)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(66)
- MDM2(12)
- p53(123)
- PC-PLC(4)
- PKD(8)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(146)
- Other Apoptosis(885)
- APC(6)
- PD-1/PD-L1 interaction(90)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(31)
- Cat.No. 产品名称 Information
-
GC92099
MSG606 (trifluoroacetate salt)
cyclo(CH2)3CO-Gly-His-D-Phe-Arg-D-Trp-Cys)-Asp-Arg-Phe-Gly-NH2
MSG606 (trifluoroacetate salt)是黑皮质素受体1的肽拮抗剂(MC1R;对人类受体的IC50=17 nM)和γ-黑素细胞刺激激素(γ-MSH)的衍生物。 -
GC92074
1,2,3-Trioleoyl Glycerol-d5
Glyceryl Trioleate-d5; TG(18:1/18:1/18:1)-d5; Triolein-d5
1,2,3-Trioleoyl Glycerol-d5用于GC-或LC-MS定量1,2,3-三油基甘油的内标。 - GC92066 RMC-6236 RMC-6236是gtp结合RAS的非共价抑制剂。
-
GC92037
JQKD82 (hydrochloride)
JADA82; PCK82
JQKD82 (hydrochloride)是KDM5-C49的前药形式,KDM5-C49是Jumonji AT-rich相互作用结构域1A (JARID1A)的抑制剂,也称为赖氨酸特异性去甲基酶5A (KDM5A)。 - GC92023 PTX80 PTX80是p62的拮抗剂(对人受体的IC50=31.18nM)。
-
GC91977
TrkB Agonist Prodrug R13
TrkB-IN-1; Tropomyosin-related Kinase B Agonist Prodrug R13; Tropomyosin-related Kinase B Inhibitor 1
TrkB Agonist Prodrug R13(R13)是原肌球蛋白相关激酶B(TrkB)激活剂7,8-二羟基黄酮的前药形式。 -
GC91967
LMTK3 Inhibitor C28
Lemur Tyrosine Kinase 3-IN-1; Lemur Tyrosine Kinase-IN-C28; Lemur Tyrosine Kinase 3 Inhibitor 1; Lemur Tyrosine Kinase Inhibitor C28; LMTK3-IN-1; LMTK3-IN-C28; LMTK3 Inhibitor 1
LMTK3 Inhibitor C28是一种多激酶抑制剂。 -
GC74733
Methoxyamine-d3 Hydrochloride
O-Methylhydroxylamine-d3 hydrochloride
Methoxyamine-d3 Hydrochloride (O-Metldroxylamine-d3)是氘标记的甲氧基胺氯。 - GC74721 Geraniol-d6 (Major) Geraniol-d6 (Major)是氘代标记的Geraniol Major。
-
GC74719
ASC-69
APY69
ASC-69(APY69)是一种有效且有前景的PD-1/PD-L1小分子抑制剂。 - GC74684 Topoisomerase II inhibitor 14 Topoisomerase II inhibitor 14(化合物2f)是拓扑异构酶II的强效抑制剂,具有抗癌活性。
- GC74668 3-Methoxy-9H-Carbazole 3-Methoxy-9H-Carbazole诱导caspase-3活性和细胞产生活性氧。
- GC74630 TI17 TI17是甲状腺激素受体相互作用蛋白Trip13的抑制剂,具有抗癌活性。
-
GC74627
Rosnilimab
ANB030
Rosnilimab是一种靶向PD-1的人源化IgG1-κ抗体。 -
GC74623
Reozalimab
LY3434172
Reozalimab是一种靶向PD-1/PD-L1的双特异性抗体。 -
GC74620
Zilovertamab vedotin
VLS-101; MK-2140
Zilovertamab vedotin(VLS-101)是一种新型抗体-药物偶联物,其包含人源化单克隆抗体齐洛他单抗和抗微管细胞毒素单体韦多汀。 -
GC74617
SHR-1701
Retlirafusp alfa
SHR-1701(Retlirafusp alfa)是一种用于癌症研究的靶向PD-L1和TGF-β的双功能融合蛋白。 -
GC74616
Retifanlimab
瑞弗利单抗
Retifanlimab是一种抗程序性细胞死亡蛋白1 (anti-PD-1)单克隆抗体。 -
GC74614
Eftozanermin alfa
ABBV-621
Eftozanermin alfa(ABBV-621)是第二代肿瘤坏死因子相关凋亡诱导配体受体(TRAIL-R)激动剂。 -
GC74611
Peresolimab
LY-3462817
Peresolimab是一种靶向PD-1的人源化IgG1-κ抗体。 -
GC74608
Elranatamab
埃纳妥单抗; PF-06863135
Elranatamab (PF-06863135)是一种抗cd3e /TNFRSF17人IgG2κ单克隆抗体。 -
GC74604
Linvoseltamab
利伏赛坦单抗; REGN5458
Linvoseltamab是一种针对BCMA (TNFRSF17)和CD3 epsilon的双特异性抗体。 -
GC74601
Cosibelimab
柯希利单抗; CK-301; TG-1501
Cosibelimab (ck - 301;TG-1501)是一种高亲和力的全人源性PD-L1阻断单克隆抗体,可结合PD-L1并阻断其与PD-1的相互作用。 -
GC74597
Ravagalimab
拉瓦加利单抗; ABBV-323
Ravagalimab(ABBV-323)是CD40拮抗剂(EC50:3.7nM)。 -
GC74595
Prolgolimab
帕洛利单抗; BCD-100
Prolgolimab(BCD-100)是一种含有Fc沉默“LALA”突变的人IgG1抗PD-1单克隆抗体。 -
GC74592
Pacmilimab
帕克米利单抗; CX-072
Pacmilimab (CX-072)是一种有效的PD-L1抑制剂。 -
GC74585
Obexelimab
奥贝利单抗; XmAb5871
Obexelimab(XmAb5871)是一种人源化抗CD19抗体。 -
GC74583
Nofazinlimab
CS1003
Nofazinlimab (CS1003)是一种人源IgG4抗pd -1单克隆抗体。 -
GC74580
Mitazalimab
米佐利单抗; ADC-1013; JNJ-64457107
Mitazalimab(ADC-1013;JNJ-64457107)是FcγR依赖性CD40激动剂,具有肿瘤导向活性。 -
GC74572
Lilotomab
利洛托单抗; HH1
Lilotomab(0-40µg/mL;12 d)降低DOHH2和Ramos细胞的克隆性存活。 -
GC74568
Latikafusp
AMG 256
Latikafusp (AMG 256)是一种双功能融合蛋白,包括PD-1靶向抗体和IL-21突变蛋白,旨在向PD-1+细胞提供IL-21通路刺激。 -
GC74564
Ivonescimab
依沃西单抗; AK112
Ivonescimab (AK112)是一种PD-1/VEGF双特异性抗体。 -
GC74563
Iratumumab
伊妥木单抗; MDX-060
Iratumumab (MDX-060)人抗cd30 IgG1κ单克隆抗体。 - GC74560 Inezetamab Inezetamab是一种双特异性抗CD40和抗MSLN IgG1单克隆抗体。
-
GC74556
Gilvetmab
吉维单抗
Gilvetmab是一种有效的犬化抗pd -1单克隆抗体。Gilvetmab阻断PD-1与其配体PDL-1的相互作用。 -
GC74553
Geptanolimab
杰洛利单抗; APL-501; CBT-501; GB-226
Geptanolimab(CBT-501)是一种针对程序性死亡-1(PD-1)的人源化IgG4k单克隆抗体。 -
GC74543
Ezabenlimab
埃本利单抗; BI-754091
Ezabenlimab (BI-754091)是一种抗pd -1单抗,结合常数Kd值为6 nM (CHO细胞)。 -
GC74542
Cinrebafusp alfa
PRS 343
Cinrebafusp alfa(PRS 343)是一种高亲和力CD137/HER2双特异性抗毒蛋白药物。 -
GC74541
Socazolimab
索卡佐利单抗; ZKAB001; STI-1014; STI-A1014
Socazolimab(ZKAB001)是一种抗PD-L1单克隆抗体。 -
GC74538
Sotevtamab
索泰妥单抗; 16B5; AB-16B5
Sotevtamab (16B5)是一种人源IgG2抗聚簇素单克隆抗体(mAb)。 -
GC74534
Tagitanlimab
HBM-9167; KL-A167
Tagitanlimab (HBM-9167)是一种人源抗pd - l1抗体(IgG1κ型)。 -
GC74532
Tuvonralimab
托沃瑞利单抗; PSB-205; QL1706 (iparomlimab/tuvonralimab); PBS105
Tuvonralimab (psb - 205;QL1706)是一种双免疫检查点阻断剂,含有抗pd -1 IgG4和抗ctla -4 IgG1抗体的混合物,Iparomlimab和Tuvonralimab。 -
GC74515
Benufutamab
GEN1029
Benufutamab(GEN1029)是一种死亡受体5(DR5)特异性激动抗体。 -
GC74507
Asunercept
APG101; CAN008
Asunercept (APG101;CAN008)是一种靶向CD95L的可溶性CD95-Fc融合蛋白。 -
GC74501
Adebrelimab
阿得贝利单抗; SHR-1316
Adebrelimab(SHR-1316)是一种人源化IgG4单克隆PD-L1(PD-1/PD-L1)抗体。 -
GC74500
Acasunlimab
GEN1046
Acasunlimab (GEN1046)是针对PD-L1和4-1BB的双特异性抗体(bsAb)。 -
GC74486
Lexatumumab
来沙木单抗; HGS-ETR 2; ETR2-ST01
Lexatumumab(HGS-ETR 2)是一种人激动性TRAIL受体2(TRAIL-R2、DR5、APO-2)IgG4κ型单克隆抗体。 -
GC74482
Drozitumab
曲齐妥单抗; PRO 95780; rhuMAb-DR 5; Anti-Human DR5 Recombinant Antibody
Drozitumab(PRO 95780)是一种结合死亡受体DR5的人激动性单克隆抗体。 -
GC74477
Tigatuzumab
替加组单抗; CS-1008; Anti-Human TRAIL-R2 Recombinant Antibody
Tigatuzumab(CS-1008)是一种靶向死亡受体5(DR5)的人源化IgG1单克隆抗体。 -
GC74476
Seribantumab
瑟瑞妥单抗; SAR 256212; MM 121; Anti-Human ERBB3/ErbB 3 Recombinant Antibody
Seribantumab (MM 121)是一种靶向HER3的全人源IgG2单克隆抗体。